• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Microbiol Biotechnol . Domain-Specific Impacts of Spike Protein Mutations on Infectivity and Antibody Escape in SARS-CoV-2 Omicron BA.1

tetano

Editor, Senior Moderator
J Microbiol Biotechnol


. 2025 Sep 16:35:e2507040.
doi: 10.4014/jmb.2507.07040. Domain-Specific Impacts of Spike Protein Mutations on Infectivity and Antibody Escape in SARS-CoV-2 Omicron BA.1

Tae-Hun Kim[SUP] 1 [/SUP], Sojung Bae[SUP] 1 [/SUP], Jinjong Myoung[SUP] 1 [/SUP]



Affiliations
Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic began in Wuhan, China in late 2019, rapidly spreading worldwide and causing the COVID-19 pandemic. The virus evolved through multiple variants, with Omicron (first detected in late 2021) becoming dominant due to its extensive spike mutations, which enhanced immune evasion despite reduced infectivity compared to earlier strains. Here, we systematically evaluated the functional consequences of these mutations by generating pseudoviruses expressing spike proteins with domain-specific alterations. Mutations in the N-terminal domain (NTD) significantly enhanced pseudoviral infectivity, while receptor-binding domain (RBD) mutations markedly reduced infectivity. Importantly, NTD-mediated enhancement was attenuated when combined with RBD mutations, highlighting a complex interplay between spike regions. Despite lower infectivity compared to Delta, BA.1 pseudoviruses harboring RBD mutations exhibited robust resistance to neutralizing monoclonal antibodies, including casirivimab and imdevimab, with IC[SUB]50[/SUB] values exceeding assay limits. These findings indicate that Omicron BA.1's rapid global spread is driven by enhanced immune evasion conferred by RBD mutations, even at the expense of viral entry efficiency. Our domain-specific analysis underscores the critical roles of spike protein mutations in shaping Omicron BA.1's transmissibility and antibody escape, informing strategies for therapeutic and vaccine development.

Keywords: Omicron BA.1; SARS-CoV-2; domain; immune evasion; infectivity; mutation.

 
Back
Top Bottom